Thank you for subscribing.

Please check your email to confirm.

Unsubscribe success..

You already subscribed and confirmed.

Please check your email.

You already subscribed.

Please check your email to confirm.

Stroke Medical Closes Series B, in a Move to Defeat China’s Chronic Problem
Stroke Medical Closes Series B, in a Move to Defeat China’s Chronic Problem
Operation room. Image: Credit to Piron Guillaume on Unsplash.
Associated Company
EqualOcean EqualOcean

 A Shanghai-based medical device producer, Stroke Medical (心玮医疗), announced that it had raised nearly CNY 100 million in its Series B financing round. This round was led by Grand Yangtze Capital (长江国弘), Chengyu Capital (盛宇投资), and Hidea VC (海达投资).

Stroke Medical is located in Zhangjiang Hi-Tech Park in Shanghai, where it belongs to a cluster of medical device producers. The company is focusing on the prevention and treatment of ischemic stroke.

There are currently two core products being developed: a device to facilitate Percutaneous Coronary Intervention (PCI) and a Left Atrial Appendage (LAA) occlusion device. PCI is a non-surgical procedure that uses a thin, flexible tube to place a stent to open up blood vessels in the heart that have been narrowed due to atherosclerosis. The second core product series, LLA devices, are used to implant a 'Watchman', – which monitors the heart for the signs of a stroke.

Watchman procedures are among the safest, and there have been over 80,000 Watchman implants with a success rate of over 94.3% in the US since 2015.

Stroke is amongst the top 10 causes of death in China. The number of people suffering from stroke in China over 40 years old is 12.42 million, with the disease killing over 2 million people in 2018. The numbers will multiply as China’s population ages. The stroke intervention market is expected to reach CNY 3 billion by 2020 in China. 

Yet, the Chinese stroke-fighter is not the only supplier of this gigantic market; indeed it competes with some of the world’s largest producers, including, among others, Medtronic (MDT: NYSE) and Stryker Corporation (SYK: NYSE). But the company claimed to produce cost-efficient products compared to those of its rivals from the US.

"Although the domestic stroke intervention market has been developing strikingly, it is still facing the clinical shortage of stroke interventional devices. There is an urgent need for more and better stroke intervention devices that are produced by domestic players in the mainlann," claimed Wang Guohui (王国辉), the CEO of Stroke Medical.

In the Medical Devices field, China has yet to have a presence, even in the domestic market. However, there are more companies that are challenging this phenomenon. Chinese companies are especially being more visible, particularly in relatively smaller value-added medical products such as stents and needles.

Micro-Tech (南微医学) (688029: SH) is yet another medical devices and equipment developer from Nanjing. It was amongst the first batch of the companies to have been traded on China’s STAR Board.

Stroke Medical's products are certified by CFDA, and there is no related patent dispute; claimed the company. However, the patent question is one of the major variables that need to be watched in the upcoming period.

Enterprise Information

EqualOcean is a leading industry tech media and an investment research company.
CATEGORIES: AI, Research
Last Funding Type
Series C
Number of Employees
200
Number of Funding Rounds
6
Total Funding Amount
26.79M

Enterprise Information

EqualOcean
EqualOcean is a leading industry tech media and an investment research company.
CATEGORIES: AI, Research
Last Funding Type
Series C
Number of Employees
200
Number of Funding Rounds
6
Total Funding Amount
26.79M

Reach the Author!

Ask the author questions about the copied text

MOST READ

THE LATEST

Any Question

EqualOcean is a leading industrial tech media and investment research company that focuses on technological and industrial innovation in China.

We aim to assist Chinese entrepreneurial enterprises to break into the global market and provide overseas investors, VCs, and enterprises with a deeper understanding of China's business environment and to seize opportunities in China.

Join over 800,000 of your peers